Author + information
- Karim Abdur Rehman,
- Muhammad Khan,
- Arsalan Rehmani,
- Maryam Taufeeq,
- Muhammad Adil Sheikh,
- Kaneez Fatima,
- Sajjad Gul and
- Haris Riaz
Introduction: Despite FDA approval, the cardiovascular safety of anti-obesity drugs (naltrexone-bupropion, phenteramine-topiramate, liraglutide, orlistat and lorcaserin) remains unknown. This is important given the withdrawal of historical weight loss agents amidst safety concerns.
Methods: Large randomized control trials were identified on PubMed where the drug was compared with placebo. A random effects model was used to pool the studies given the heterogeneity between studies. References of these studies were hand searched to identify missing data.
Results: 13 studies (mean follow up= 55 weeks) including 19,806 patients in the treatment arm and 14,921 in the placebo arm were selected. Cardiovascular safety end points such as valvulopathy (n=4), arrhythmias (n=2), myocardial infarction (n=4) and cardiovascular death (n=2) were reported less frequently, than blood pressure (n=11) and heart rate (n=11). Pooled analysis showed no significant difference (RR=1.06, CI=0.83-1.34, P=0.65) in new vavulopathy, amongst users.
Conclusions: Our meta-analysis demonstrates a paucity of evidence on the cardiovascular safety of FDA approved anti-obesity drugs. Studies on these agents were limited by careful selection of patient populations, sample size, duration of follow ups, and were underpowered to determine key safety end points. Clinicians should consider these important limitations and await results of post-marketing surveillance, which are underway, before widespread generalization.
Moderated Poster Contributions
Prevention Moderated Poster Theater, Poster Hall, Hall C
Friday, March 17, 2017, 4:15 p.m.-4:25 p.m.
Session Title: Obesity Management in 2017: Weighing the Issues
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1173M-07
- 2017 American College of Cardiology Foundation